0000899243-21-036822.txt : 20210921
0000899243-21-036822.hdr.sgml : 20210921
20210921180014
ACCESSION NUMBER: 0000899243-21-036822
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200205
FILED AS OF DATE: 20210921
DATE AS OF CHANGE: 20210921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Evans John M.
CENTRAL INDEX KEY: 0001786304
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39208
FILM NUMBER: 211267369
MAIL ADDRESS:
STREET 1: C/O BEAM THERAPEUTICS INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beam Therapeutics Inc.
CENTRAL INDEX KEY: 0001745999
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-327-8775
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-02-05
2020-08-17
0
0001745999
Beam Therapeutics Inc.
BEAM
0001786304
Evans John M.
C/O BEAM THERAPEUTICS INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
1
1
0
0
CEO
Stock Option (Right to Buy)
0.67
2020-02-05
4
A
0
99336
0.00
A
2028-05-08
Common Stock
99336
99336
D
Stock Option (Right to Buy)
4.22
2020-02-05
4
A
0
53964
0.00
A
2029-02-13
Common Stock
53964
53964
D
On August 17, 2020, the reporting person filed a Form 4 which inadvertently omitted certain options held by the reporting person on such date (the "Original Form 4").
On May 8, 2018, the reporting person was granted an option to purchase 198,672 shares of common stock of Beam Therapeutics Inc. (the "Company"). The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's initial public offering ("IPO") (which closing price hurdle has been achieved) (the "Price Condition"). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable.
(Continued from Footnote 2) The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO.
On February 13, 2019, the reporting person was granted an option to purchase 107,929 shares of common stock of the Company. The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's IPO (which closing price hurdle has been achieved). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable. The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO.
By: /s/ Christine Bellon, Attorney-in-fact
2021-09-21